Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Modafinil
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Social views=== The use of modafinil as a supposed cognitive enhancer may be considered as cheating, unnatural, or risky.<ref name="The rise of smart drugs-2016">{{cite web | vauthors=Macnaughton O | url=https://www.tatler.com/article/the-rise-of-smart-drugs | title=The rise of smart drugs | date=March 16, 2016 | work=Tatler | access-date=November 15, 2023 | archive-date=November 15, 2023 | archive-url=https://web.archive.org/web/20231115162141/https://www.tatler.com/article/the-rise-of-smart-drugs | url-status=live }}</ref> The [[University of Sussex]] explained that it is a prescription drug and the decision should be made by the [[Health professional|doctor]] on whether to prescribe modafinil to a student.<ref name="We asked Sussex University if Modafinil is cheating-2017">{{cite web | vauthors=Farrell K | url=https://thetab.com/uk/sussex/2017/11/06/asked-sussex-university-modafinil-cheating-22575 | title=We asked Sussex University if Modafinil is cheating | date=November 6, 2017 | work=The Sussex Tab | access-date=November 15, 2023 | archive-date=November 15, 2023 | archive-url=https://web.archive.org/web/20231115162143/https://thetab.com/uk/sussex/2017/11/06/asked-sussex-university-modafinil-cheating-22575 | url-status=live }}</ref> As a matter of [[bioethics]], the US [[President's Council on Bioethics]] argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual.<ref name="Porsdam Mann-2018">{{cite journal |doi=10.1080/17449642.2018.1443050 |title=Is the use of modafinil, a pharmacological cognitive enhancer, cheating? |date=2018 |vauthors=Porsdam Mann S, de Lora Deltoro P, Cochrane T, Mitchell C |journal=Ethics and Education |volume=13 |issue=2 |pages=251β267 |s2cid=149138516 |url=https://philpapers.org/archive/PORITU.pdf |access-date=February 2, 2024 |archive-date=February 2, 2024 |archive-url=https://web.archive.org/web/20240202114822/https://philpapers.org/archive/PORITU.pdf |url-status=live }}</ref> Alternately, people in environments like [[Wall street trader|Wall Street trading]] may not view the use of modafinil as cheating, believing that if modafinil can give them an edge and they are aware of the risks involved, it should not be considered as cheating.<ref name="Robert-2013">{{cite magazine|magazine=New York Magazine|url=https://nymag.com/news/intelligencer/modafinil-2013-4/|title=The Real Limitless Drug Isn't Just for Lifehackers Anymore|date=March 29, 2013| vauthors = Robert K |access-date=March 16, 2024|archive-date=December 26, 2023|archive-url=https://web.archive.org/web/20231226213829/https://nymag.com/news/intelligencer/modafinil-2013-4/|url-status=live}}</ref> Due to such varying views, modafinil users for narcolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.<ref name="pmid32023288">{{cite journal | vauthors = Teodorini RD, Rycroft N, Smith-Spark JH | title = The off-prescription use of modafinil: An online survey of perceived risks and benefits | journal = PLOS ONE | volume = 15 | issue = 2 | pages = e0227818 | date = 2020 | pmid = 32023288 | pmc = 7001904 | doi = 10.1371/journal.pone.0227818 | doi-access = free | title-link = doi | bibcode = 2020PLoSO..1527818T }}</ref><ref name="pmid28179647">{{cite journal | vauthors = Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, Overeem S | title = Narcolepsy | journal = Nature Reviews. Disease Primers | volume = 3 | pages = 16100 | date = February 2017 | pmid = 28179647 | doi = 10.1038/nrdp.2016.100 | s2cid = 266008273 | url = http://www.hal.inserm.fr/inserm-01484949/file/nrdp2016100_Primer_1486657828_1.pdf }}{{Dead link|date=March 2024 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)